| Name | Title | Contact Details |
|---|
Stanton Territorial Health Authority is a Yellowknife, NT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
At Medical Solutions, we connect care for our clients, traveling nurses and clinicians, and our internal employees. We help our clients find the perfect clinical, community and cultural fit with their traveling nurses and staff. Our travelers receive the best service in the industry from recruiters invested in their professional and personal success. Our employees work for a mission they believe in, with pride of representing one of the most respected brands in the healthcare staffing industry. We serve acute-care hospitals, post-acute care facilities, community health centers and other healthcare settings nationwide. We offer travel staffing as well as a managed service provider (MSP) program, strike solutions for hospitals, and a rapid response program for hospitals with urgent, flexible staffing needs. Our dedicated Client Managers ensure your facility`s unique needs, challenges and goals are met in a cost-effective manner.
National Clinical Research is a Richmond, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Majestic Care is a company that provides community-based senior care throughout Indiana, Ohio, and Michigan. They specialize in clinical services based on local needs, including short-term rehabilitation, long-term care, and memory care.
Nanoscope Therapeutics is advancing gene therapy using light-sensitive molecules and light-assisted gene delivery for giving sight to the millions of blind individuals suffering from retinal degenerative disease, for which no cure exists. Nanoscope is focused on proprietary ambient light-activated optogenetic therapy to restore vision in people suffering from various inherited retinal degenerative diseases including Retinitis Pigmentosa, Stargardt, and dry AMD. Genetic retinal degenerative diseases cause vision loss as cells of the retina gradually become dysfunctional. Nanoscope`s proprietary gene therapies correct the condition by delivering light-sensitive molecules, called Multi-Characteristic Opsins (MCO), into retinal cells.